Crescent Biopharma, Inc. CBIO
13.99
(0.25)
(1.76%)
as of 25 Sep
- Market cap
- $528.9M
- P/E
- 0.0×
Follow CBIO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(78.63%) | (167.75%) | (176.92%) | (112.14%) | |
| (63.33%) | (111.59%) | (158.03%) | (97.08%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(42.38%) | (76.42%) | (88.91%) | (102.34%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(1.47) | (6.95) | (2.33) | (2.35) | |
Free Cash Flow |
(24.36) | (72.42) | (70.68) | (71.85) | |
Capital Expenditures |
(0.70) | (0.89) | (1.07) | 0.83 | |
Piotroski F-Score |
— | — | 4.00 | — | |
| Other line items | |||||
Cash ROIC |
(9.47%) | (17.19%) | (18.66%) | (21.71%) | |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 11,932.52% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,434.58% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 1,328.52% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.49 | 0.46 | 0.43 | 0.44 | |
Depreciation/Fixed assets |
0.05 | 0.10 | 0.16 | 0.24 | |
Capex/Depreciation |
(18.22) | (10.58) | (7.20) | 3.92 | |
Revenue per Share |
0.00 | 0.00 | 0.04 | 0.00 | |
Operating CF per Share |
(1.43) | (6.87) | (2.29) | (2.38) | |
Capex per Share |
(0.04) | (0.09) | (0.04) | 0.03 | |
Capex to Sales |
0.00 | 0.00 | 0.88 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | (13,304.63%) | 0.00% |
Columns are period end dates